Significant Progress in Phase III Liver Cancer and Phase I/II Ovarian Cancer Studies  Supported with Solid Fundamentals and a Strong Balance Sheet                Company to Hold Conference Call on Friday, May 11, 2018 at 11:00 a.m. EDT LAWRENCEVILLE, N.J.

LAWRENCEVILLE, N.J. , May 08, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that Michael H. Tardugno , Chairman, President and Chief Executive Officer of Celsion , will present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference being held on May 8 – 9,

LAWRENCEVILLE, N.J. , May 04, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2018 and provide an update on its development programs for ThermoDox®, its proprietary

   LAWRENCEVILLE, N.J. , April 12, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced a presentation and discussion of ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin in Phase III development for the

DMC Unanimously Recommends Continuation of OPTIMA Study Based on Safety Data From 411 Patients; Enrollment Now at 80% Blinded Progression-Free Survival (PFS) Rate in the OPTIMA Study is Consistent With the Subgroup Patient Population That Showed Benefit in the HEAT Study ThermoDox®-Highlighted

Celsion Enters 2018 with Solid Fundamentals, a Strong Balance Sheet and             an Advancing Clinical Pipeline Company to Hold Conference Call on Tuesday, March 27, 2018 at 11:00 a.m. EDT LAWRENCEVILLE, N.J. , March 27, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology

LAWRENCEVILLE, N.J. , March 20, 2018 (GLOBE NEWSWIRE) --  Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the year ended December 31, 2017 and provide an update on its development programs for ThermoDox®, its

Company to Discuss its Ongoing Pivotal Phase III and its Phase II Clinical Studies in Oncology    LAWRENCEVILLE, N.J. , March 12, 2018 (GLOBE NEWSWIRE) --  -- Celsion Corporation  (NASDAQ: CLSN), an oncology drug development company, today announced that Michael Tardugno , Chairman, President and

Discussion Included Overview of Ovarian Cancer Treatment Landscape and Celsion’s Immunotherapy Product Candidate, GEN-1 Presentation Available on Celsion’s Website LAWRENCEVILLE, N.J. , March 05, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) today announced that Premal H.

-Thesis Supporting the Phase III OPTIMA Study Chosen for the Presidential Selection Lecture by the Academic Committee - - Celsion to Host Symposium on Hepatocellular Carcinoma at International Liver Congress 2018 in April -